Εξειδίκευση τύπου :	Άρθρο σε επιστημονικό περιοδικό
Τίτλος:	Estrogen receptors β1 and β2 are associated with distinct responses of estrogen receptor α-positive breast carcinoma to adjuvant endocrine therapy
Δημιουργός/Συγγραφέας:	Dhimolea E. Tiniakos D.G. Chantzi N.T. Goutas N. Vassilaros S.D. [EL] Μήτσιου, Δήμητρα[EN] Mitsiou, Dimitra J. [EL] Αλέξης, Μιχαήλ Ν.[EN] Alexis, Michael N.
Εκδότης:	Elsevier Ireland Ltd
Ημερομηνία:	2015
Γλώσσα:	Αγγλικά
ISSN:	0304-3835
DOI:	10.1016/j.canlet.2014.12.022
Άλλο:	PubMed ID: 25524554
Περίληψη:	Our purpose was to assess whether and how ERβ1 and/or ERβ2 expression status could predict response of early stage ERα-positive breast carcinoma to adjuvant endocrine therapy (AET). ERβ1 and ERβ2 expression were determined using immunohistochemistry. ERβ1- and ERβ2-positivity were derived from receiver operating characteristic analysis and the median percentage of immunostained tumor cells, respectively. Patients with recurrent disease were grouped according to whether they relapsed within 4 years or after 4 years from surgery. The predictive significance of ERβ1 and ERβ2 was determined using Kaplan-Meier survival analysis and Cox proportional hazards regression analysis. ERβ1-positivity in the first-4-year relapse patient group was lower and ERβ2-positivity in the post-4-year relapse group was higher compared with no-relapse group. ERβ1-positivity was associated with lower tumor size and longer first-4-year disease-free survival, while ERβ2-positivity was associated with shorter post-4-year disease-free survival. Cox multivariate analysis including ERβ1, ERβ2 and established clinico-pathological variables showed that ERβ1-positivity was an independent predictor of lower first-4-year risk of relapse. Thus, low ERβ1 expression and high ERβ2 expression are markers for identification of AET-treated ERα-positive breast carcinoma patients at risk of early and late relapse, respectively.
Τίτλος πηγής δημοσίευσης:	Cancer Letters
Τόμος/Κεφάλαιο:	358
Τεύχος:	1
Σελίδες:	37-42
Θεματική Κατηγορία:	[EL] Βιοχημεία[EN] Biochemistry [EL] Θεραπευτική. Φαρμακολογία[EN] Therapeutics.Pharmacology
Λέξεις-Κλειδιά:	Breast carcinoma Endocrine therapy ERβ1 ERβ2 Immunohistochemistry
Αξιολόγηση από ομότιμους (peer reviewed):	Ναι
Κάτοχος πνευματικών δικαιωμάτων:	© 2014 Elsevier Ireland Ltd.
Σημειώσεις:	THALES 85355; 03ED644. This study was supported by EU Social Fund and Greek national funds through the Operational Program ‘Education and Lifelong Learning’ (Project THALES 85355 ) and the NSRF Research Funding Program (Project 03ED644 ).
Εμφανίζεται στις συλλογές:	Ινστιτούτο Χημικής Βιολογίας - Επιστημονικό έργο